ArticleJournal of thoracic disease2025
Burden of silicosis based on the Global Burden of Disease Study 2021: trend analysis of incidence, mortality, and disability-adjusted life years, and projections for the next 30 years.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Macrophage-Derived Ferritin Exacerbates Silica-Induced Pulmonary Fibrosis via PIK3R2-Mediated Fibroblast Differentiation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Investigating the Mechanism of Astragalus mongholicus-Mediated Treatment of Silicosis in Mice from the Perspective of Alternative Splicing.Current drug targets · 2026Article
- Tools of the trade: leveraging 3DFrontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Silicosis, an occupational disease caused by chronic silica exposure, has a high global burden and limited treatment options. This study analyzed the epidemiological trends and future projections of silicosis based on data from the Global Burden of Disease (GBD), aiming to provide data support for public health interventions. Methods: We extracted and analyzed the data on the incidence, mortality, and disability-adjusted life years (DALYs) of silicosis, as well as the age-standardized rate (ASR) of silicosis from the GBD Study 2021. Using these data, we describe the trends in five dimensions: global, regional, national, age, and sex. We used Joinpoint regression software (V.5.2.0) to calculate the average annual percent changes (AAPCs) in the ASRs from 1990 to 2021. Silicosis trends from 2022 to 2050 were predicted using Bayesian Age-Period-Cohort (BAPC) and Autoregressive Integrated Moving Average (ARIMA) models. Results: From 1990 to 2021, the global incidence of silicosis, number of deaths, and DALYs showed an upward trend. However, the corresponding ASRs all showed decreasing trends, with AAPC values of -1.1% (-1.1% to -1.0%), -2.5% (-2.7% to -2.3%), and -2.5% (-2.7% to -2.3%), respectively. However, the burden of silicosis varied significantly across countries and regions, with China, South Africa, and Chile having a silicosis age-standardized incidence rate (ASIR) and age-standardized DALYs rate (ASDR) well above the global average. In addition, the ASIR and ASDR of silicosis were generally higher among men. There were also differences between regions at different socioeconomic levels, with the DALYs burden of silicosis being lowest among males and females in low social demographic index (SDI) regions and highest among males in medium and high SDI regions. The BAPC model projected a gradual decrease in the silicosis burden from 2022 to 2050. Conclusions: Although the disease burden of silicosis showed a decreasing global trend from 1990 to 2021, it is still a global public health concern. Effective preventive and curative measures should be taken to address the challenges posed by silicosis and to protect the lives and health of workers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.